WASHINGTON — It’s two weeks until Congress leaves town in August, and a prominent House panel is throwing a wrench in what seemed like a smooth path forward for legislation to require more transparency in health care prices, and to change Medicare drug payments.
The House Energy & Commerce Committee already introduced, held multiple hearings on, and unanimously passed out of committee a package of legislation including transparency requirements for hospitals and pharmacy benefit managers and a so-called “site-neutral” pay policy for drugs administered in doctors’ offices.
But leaders of the House Ways & Means Committee are planning to release their own health care legislation this month, complicating the chamber’s path to passing something soon, four lobbyists told STAT.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect